Guardant Health (GH) announced a strategic collaboration with Pfizer (PFE) to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to: utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies; evaluate the clinical utility of circulating tumor DNA level as a surrogate endpoint to monitor therapy response and related blood-based epigenomic analyses. The collaboration will also provide Pfizer with access to Guardant’s liquid biopsy tests in China for their global clinical trials that include China cohorts. In July 2022, Guardant announced a strategic partnership with Adicon Holdings, an independent clinical laboratory company based in China, to offer Guardant tests to biopharmaceutical companies conducting clinical trials in China. Cancer is the leading cause of death in China, with over three million cancer-related deaths in 2020.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Strategic Advancements in Multi-Cancer Detection Reinforce Buy Rating
- Guardant Health price target raised to $60 from $56 at BofA
- Guardant Health price target lowered to $55 from $60 at Barclays
- Guardant Health: Poised for Growth with Innovative Precision Oncology Solutions
- Guardant Health initiated with an Outperform at Mizuho